Cytek Biosciences (NASDAQ:CTKB) Releases Quarterly Earnings Results, Beats Expectations By $0.02 EPS

Key Points

• Cytek beat quarterly expectations: It reported a loss of $0.05 per share, $0.02 better than consensus, and revenue of $53.23 million versus estimates of $53.05 million.
• Sales trends were mixed, with high-end instruments standing out: Revenue grew 2%, while Aurora and Aurora Evo placements rose 23%; declines in APAC and biopharma, CRO and distributor sales weighed on results.
• Margins improved, but profitability remained pressured: Gross margin expanded nearly 600 basis points to 59%, while adjusted EBITDA fell to $0.7 million from $2.5 million a year earlier. Management maintained its full-year revenue outlook.

Cytek Biosciences (NASDAQ:CTKB - Get Free Report) released its earnings results on Wednesday. The company reported ($0.05) EPS for the quarter, topping analysts' consensus estimates of ($0.07) by $0.02, FiscalAI reports. Cytek Biosciences had a negative net margin of 38.98% and a negative return on equity of 12.40%. The business had revenue of $53.23 million during the quarter, compared to analysts' expectations of $53.05 million.

Here are the key takeaways from Cytek Biosciences' conference call:

• Revenue growth was modest and uneven: Q3 revenue rose 2% to $53.2 million, with U.S. revenue up 12% and academic and government sales up 38%; APAC revenue fell 25% year over year, while biopharma, CRO and distributor revenue declined 17%.
• High-end instrument demand was a bright spot. Combined Aurora and Aurora Evo placements increased 23%, with Evo placements nearly doubling; high-end Full Spectrum Profiling instrument revenue grew 11%.
• Gross margin improved, but adjusted EBITDA declined. Gross margin expanded nearly 600 basis points to 59%, helped by lower manufacturing overhead, material costs and tariffs; adjusted EBITDA was $0.7 million versus $2.5 million a year earlier, reflecting higher operating expenses and lower investment income.
• Cytek maintained its full-year revenue outlook and narrowed its 2026 guidance to $208 million–$211 million. Management expects Q4 revenue to rise meaningfully with seasonal purchasing and projects adjusted EBITDA around break-even for the year.
• Patent litigation remains unresolved, but management says operations are unaffected. A jury found infringement under the doctrine of equivalents on one claim, and Cytek is seeking to overturn the verdict; the company said it can continue selling and shipping products and expects litigation expenses to decrease in Q4.

Cytek Biosciences Price Performance

CTKB traded down $0.08 on Wednesday, reaching $5.88. 1,567,839 shares of the company's stock were exchanged, compared to its average volume of 1,373,870. Cytek Biosciences has a twelve month low of $3.31 and a twelve month high of $6.34. The stock has a market cap of $764.28 million, a PE ratio of -9.48 and a beta of 1.15. The stock's fifty day moving average price is $5.35 and its 200-day moving average price is $4.67.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the company. Weiss Ratings reiterated a "sell (d-)" rating on shares of Cytek Biosciences in a research note on Monday, September 21st. Morgan Stanley set a $5.00 price target on Cytek Biosciences in a research note on Friday, August 7th. Finally, Stephens reiterated an "overweight" rating and set a $6.00 price target on shares of Cytek Biosciences in a research report on Friday, October 23rd. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and an average price target of $5.88.

About Cytek Biosciences

Cytek Biosciences, Inc develops and commercializes cell analysis solutions for biomedical research, clinical research and biopharmaceutical applications. The company focuses on spectral flow cytometry, a technology that enables researchers to analyze multiple characteristics of individual cells and identify complex cell populations.

Its product portfolio includes the Aurora and Northern Lights spectral flow cytometers, compact and specialized instruments, cell sorters, software and a range of fluorescent reagents.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.